Venous Thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective
Journal of Medical Economics. 2012;15(5):817-28
Authors
McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.
Process
Combined decision tree Markov model to evaluate both acute and long-term complications of VTE
Estimated VTE event rates, quality-adjusted life expectancy and direct medical costs to be estimated over a 5-year time horizon, based on current approved practice patterns in Canada
Probabilistic sensitivity analyses were performed to address model input uncertainty
Publications in other disease areas
Atrial fibrillation
Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke
Cancer
Societal costs of Er+/Her2- advanced or metastatic breast cancer in post-menopausal women in the United Kingdom
Idiopathic pulmonary fibrosis
The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review
Psoriasis
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
Rheumatoid arthritis
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK
Venous thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective